About Horizon Therapeutics
Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. We are creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
HZT-501: Phase 3 Trials
Phase 3 trials for our lead product candidate HZT-501 are being conducted under a Special Protocol Assessment (SPA) from FDA and began in March of 2007
Latest News
12.02.08
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
10.09.08
Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
10.01.08
Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
07.31.08
Horizon Therapeutics Announces Corporate Relocation to the Chicago Area